A phase 1 dose-escalation with expansion study of the antibody-drug conjugate trastuzumab duocarmazine (SYD985) in locally advanced and metastatic solid tumours and HER2-expressing... Tekijä Banerji, U, Van Herpen, C, Saura, C, Thistlethwaite, F, Lord, S, Moreno, V, Macpherson, I, Boni, V, Rolfo, C, De Vries, E, Rottey, S, Geenen, J, Eskens, F, Gil-Martin, M, Mommers, E, Koper, N, Aftimos, P